ChromaDex (NASDAQ:CDXC) Cut to “Buy” at StockNews.com

ChromaDex (NASDAQ:CDXC) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday.

Several other analysts also recently weighed in on the stock. Roth Mkm boosted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright lifted their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th.

ChromaDex Trading Up 0.5 %

Shares of ChromaDex stock opened at $6.15 on Tuesday. The business’s 50-day moving average price is $5.66 and its 200-day moving average price is $3.99. The firm has a market capitalization of $469.76 million, a PE ratio of 615.00 and a beta of 2.16. ChromaDex has a 12 month low of $1.34 and a 12 month high of $7.97.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The business had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period last year, the business earned ($0.01) earnings per share. As a group, analysts predict that ChromaDex will post 0.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the transaction, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. bought a new position in shares of ChromaDex in the 3rd quarter worth approximately $68,000. Barclays PLC raised its holdings in ChromaDex by 322.1% in the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after purchasing an additional 53,472 shares in the last quarter. Geode Capital Management LLC lifted its position in ChromaDex by 1.6% during the third quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock valued at $4,197,000 after buying an additional 17,963 shares during the period. Jane Street Group LLC grew its position in shares of ChromaDex by 100.3% in the 3rd quarter. Jane Street Group LLC now owns 45,712 shares of the company’s stock worth $167,000 after buying an additional 22,889 shares during the period. Finally, State Street Corp increased its stake in shares of ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after acquiring an additional 62,692 shares in the last quarter. 15.41% of the stock is currently owned by institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.